Vantage Health Announces Recent Scientific Updates and Corporate Developments

November 20, 2014

Redwood City, Calif.--(OTCQB: VNTH) - Vantage Health Inc. (VNTH) ("Vantage Health" or the "Company") today announces recent scientific updates and corporate developments.

Over the last three months Vantage, and its parent company, has been developing version 2.0 of its sensor technology.   Version 2.0 operates on a Bluetooth platform eliminating the need for physical connections to multiple smartphone platforms.  The new sensor is wirelessly compatible with all devices that have Bluetooth capability and will also operate with tablet technology.  Version 2.0 of the sensor has the capacity to be scaled up to 256 sensor channels.

Recently, molecular samples analyzed by the Vantage Sensor 2.0 were sent to a third party laboratory specializing in analytical environmental and pharmacological testing.  When testing for lower and higher concentrations of certain molecules, which are important biomarkers in disease detection, results suggested that the sensor may actually be more sensitive than Gas Chromatography–Mass Spectrometry (GC-MS).  A GC-MS is considered the gold standard for molecular analysis typically costing as much as six figures. Vantage plans to retail this sensor for less than $200.

A provisional patent was filed recently to protect the proprietary algorithm used to convert the nano-sensor data into useful calibrated measurements. The key inventor, formerly a NASA contractor, has been engaged to help imbed the algorithm into hand-held apps that communicate directly with the new Bluetooth device.  The Company also recruited two additional staff members; a Chief Scientist for Nanotechnology who brings 10 years of experience and a Chief Technology Officer who brings 16 years of experience. 

The Company and its partners have just completed version 3.0 of a breath capture device, which attaches directly onto the sensor.  The breath capture device allows for unlimited use of the sensor without the risk of contamination between patients and also includes a filtering mechanism, removing  water vapor in the breath, which could otherwise interfere with the molecular analysis.  The parent company will be filing another provisional patent for this technology as well.

“I am very pleased that in just a few months we have been quietly making progress demonstrated by the recruitment of senior scientists, filing of a provisional patent and the advancements of our new Vantage Sensor 2.0 making it compatible with all Bluetooth enabled devices,” stated Joseph C. Peters, President of Vantage Health, Inc.

Vantage expects to further update its shareholders this winter on preliminary clinical trial results derived from using the new sensor for human breath.



About Vantage Health Inc.

Vantage Health Inc. - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a Bluetooth device that works with any smartphone. With its foundations in advanced nanotechnology, the company’s first product, the Vantage Health Sensor, which is in development, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The first mobile App is expected to be for lung cancer screening with additional mobile healthcare Apps in the planning stages. The company has offices in Redwood City, CA and New York. For more information, please visit


This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. Such forward-looking statements may also include statements, among other things, concerning the efficacy, safety and intended utilization of Vantage’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include, among others, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Vantage may not obtain approval to market its product candidates, or outside financing may not be available to meet capital requirements. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee.


For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Annual Report on Form 10-K and other periodic and other filings Vantage files with the Securities and Exchange Commission and are available at Such forward-looking statements are current only as of the date they are made, and Vantage assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


CSIR Group, LLC.

Christine Petraglia